which displayed a broad range of G6PD activities and portion of bright cells. The data presented here confirms that the A(−) G6PD allele can result in
severe G6PD deficiency (< 10% normal activity), even if it is currently classified as a class III G6PD variant. Tests evaluated under this study are inappropriate for use in low-resource settings because of either their functional temperature working range or their complexity. The development of high-quality point-of-care tests for G6PD deficiency
that are suitable for use in low-resource areas remains a critical need for supporting treatment strategies in malaria control and elimination efforts. Adhering to harmonized evaluation protocols and using standardized reference assays will be essential for accurately assessing the performance of new diagnostic products in various populations with different G6PD deficiency traits and epidemiology.